4.6 Article

Prion strains associated with iatrogenic CJD in French and UK human growth hormone recipients

Journal

ACTA NEUROPATHOLOGICA COMMUNICATIONS
Volume 9, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s40478-021-01247-x

Keywords

Prion disease; Iatrogenic CJD; Growth hormone

Categories

Funding

  1. European Regional Development Fund POCTEFA TRANSPRION [EFA282/13]
  2. REDPRION [EFA148/16]
  3. UK Food Standards Agency Exploring permeability of the species [M03043, FS231051]
  4. European Union [FP7 222887]
  5. Alliance Biosecure Foundation [FABS201403]
  6. French research agency [ANR-15-CE18-0028]
  7. United Kingdom's Department of Health Policy Research Program
  8. Government of Scotland
  9. Medical Research Council
  10. Agence Nationale de la Recherche (ANR) [ANR-15-CE18-0028] Funding Source: Agence Nationale de la Recherche (ANR)

Ask authors/readers for more resources

The treatment with human pituitary-derived growth hormone (hGH) was responsible for a significant proportion of iatrogenic Creutzfeldt-Jakob disease (iCJD) cases, with France and the UK experiencing the largest numbers. Differences in PRNP codon 129 polymorphisms and estimated incubation periods did not lead to significant differences in the prion strains identified in hGH-iCJD cases from the two countries.
Treatment with human pituitary-derived growth hormone (hGH) was responsible for a significant proportion of iatrogenic Creutzfeldt-Jakob disease (iCJD) cases. France and the UK experienced the largest case numbers of hGH-iCJD, with 122 and 81 cases respectively. Differences in the frequency of the three PRNP codon 129 polymorphisms (MM, MV and VV) and the estimated incubation periods associated with each of these genotypes in the French and the UK hGH-iCJD cohorts led to the suggestion that the prion strains responsible for these two hGH-iCJD cohorts were different. In this study, we characterized the prion strains responsible for hGH-iCJD cases originating from UK (n = 11) and France (n = 11) using human PrP expressing mouse models. The cases included PRNP MM, MV and VV genotypes from both countries. UK and French sporadic CJD (sCJD) cases were included as controls. The prion strains identified following inoculation with hGH-iCJD homogenates corresponded to the two most frequently observed sCJD prion strains (M1(CJD) and V2(CJD)). However, in clear contradiction to the initial hypothesis, the prion strains that were identified in the UK and the French hGH-iCJD cases were not radically different. In the vast majority of the cases originating from both countries, the V2(CJD) strain or a mixture of M1(CJD) + V2(CJD) strains were identified. These data strongly support the contention that the differences in the epidemiological and genetic profiles observed in the UK and France hGH-iCJD cohorts cannot be attributed only to the transmission of different prion strains.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available